Frank Leonard's most recent trade in NovoCure Ltd was a trade of 1,679 Ordinary Shares done at an average price of $16.0 . Disclosure was reported to the exchange on March 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NovoCure Ltd | Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 16.03 per share. | 01 Mar 2024 | 1,679 | 160,938 (0%) | 0% | 16.0 | 26,909 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 16.01 per share. | 01 Mar 2024 | 840 | 160,098 (0%) | 0% | 16.0 | 13,448 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | EVP, Pres., Novocure Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 156,348 | 156,348 | - | - | Stock Options (Right to buy) | |
| NovoCure Ltd | Frank Leonard | EVP, Pres., Novocure Oncology | Grant, award, or other acquisition of securities at price $ 16.30 per share. | 27 Feb 2024 | 102,249 | 164,695 (0%) | 0% | 16.3 | 1,666,659 | Ordinary Shares |
| NovoCure Ltd | Leonard Frank | EVP, Pres., Novocure Oncology | Sale of securities on an exchange or to another person at price $ 16.14 per share. | 27 Feb 2024 | 2,078 | 162,617 (0%) | 0% | 16.1 | 33,545 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 03 Mar 2023 | 6,003 | 56,599 (0%) | 0% | 75.0 | 450,206 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 76.16 per share. | 03 Mar 2023 | 4,403 | 63,490 (0%) | 0% | 76.2 | 335,330 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 75.59 per share. | 03 Mar 2023 | 2,315 | 54,284 (0%) | 0% | 75.6 | 174,999 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 76.16 per share. | 03 Mar 2023 | 888 | 62,602 (0%) | 0% | 76.2 | 67,630 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 11,808 | 69,952 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 75.32 per share. | 02 Mar 2023 | 3,799 | 59,296 (0%) | 0% | 75.3 | 286,154 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 77.64 per share. | 02 Mar 2023 | 2,059 | 67,893 (0%) | 0% | 77.6 | 159,859 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 75.28 per share. | 02 Mar 2023 | 844 | 58,144 (0%) | 0% | 75.3 | 63,535 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 76.05 per share. | 02 Mar 2023 | 308 | 58,988 (0%) | 0% | 76.1 | 23,424 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 30,971 | 30,971 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 18,621 | 64,779 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 76.36 per share. | 28 Feb 2023 | 1,684 | 63,095 (0%) | 0% | 76.4 | 128,594 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.37 per share. | 05 Jan 2023 | 7,826 | 53,984 (0%) | 0% | 14.4 | 112,460 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 108.00 per share. | 05 Jan 2023 | 7,826 | 46,158 (0%) | 0% | 108 | 845,208 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2023 | 7,826 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 05 Jan 2023 | 7,500 | 53,658 (0%) | 0% | 11.5 | 85,950 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 108.00 per share. | 05 Jan 2023 | 7,500 | 46,158 (0%) | 0% | 108 | 810,000 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2023 | 7,500 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.15 per share. | 05 Jan 2023 | 7,183 | 53,341 (0%) | 0% | 21.1 | 151,920 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 114.00 per share. | 05 Jan 2023 | 7,183 | 46,158 (0%) | 0% | 114.0 | 818,863 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.15 per share. | 05 Jan 2023 | 7,183 | 53,341 (0%) | 0% | 21.1 | 151,920 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 05 Jan 2023 | 7,183 | 46,158 (0%) | 0% | 120 | 861,960 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2023 | 7,183 | 10,479 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2023 | 7,183 | 17,662 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 05 Jan 2023 | 5,517 | 51,675 (0%) | 0% | 7.2 | 39,447 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 108.00 per share. | 05 Jan 2023 | 5,517 | 46,158 (0%) | 0% | 108 | 595,836 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2023 | 5,517 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 119.01 per share. | 05 Jan 2023 | 2,345 | 48,111 (0%) | 0% | 119.0 | 279,073 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 117.00 per share. | 05 Jan 2023 | 1,010 | 46,158 (0%) | 0% | 117 | 118,170 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 115.03 per share. | 05 Jan 2023 | 526 | 47,168 (0%) | 0% | 115.0 | 60,508 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 108.00 per share. | 05 Jan 2023 | 417 | 47,694 (0%) | 0% | 108 | 45,036 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 11,609 | 11,609 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 6,830 | 50,456 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 76.01 per share. | 13 Oct 2022 | 6,754 | 43,626 (0%) | 0% | 76.0 | 513,372 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 84.37 per share. | 06 Oct 2022 | 6,754 | 50,380 (0%) | 0% | 84.4 | 569,835 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 77.35 per share. | 29 Sep 2022 | 6,754 | 57,134 (0%) | 0% | 77.4 | 522,422 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | President, CNS Cancers US | Sale of securities on an exchange or to another person at price $ 77.00 per share. | 22 Sep 2022 | 6,754 | 63,888 (0%) | 0% | 77 | 520,058 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 87.31 per share. | 15 Sep 2022 | 6,754 | 76,159 (0%) | 0% | 87.3 | 589,692 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 15 Sep 2022 | 5,517 | 82,913 (0%) | 0% | 7.2 | 39,447 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 5,517 | 5,517 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 15 Sep 2022 | 5,517 | 70,642 (0%) | 0% | 90 | 496,530 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 81.48 per share. | 08 Sep 2022 | 6,754 | 77,396 (0%) | 0% | 81.5 | 550,316 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.57 per share. | 06 Sep 2022 | 1,384 | 86,013 (0%) | 0% | 78.6 | 108,741 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.08 per share. | 01 Sep 2022 | 2,955 | 96,277 (0%) | 0% | 78.1 | 230,741 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 77.92 per share. | 01 Sep 2022 | 2,720 | 90,155 (0%) | 0% | 77.9 | 211,934 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 77.00 per share. | 01 Sep 2022 | 1,914 | 99,232 (0%) | 0% | 77.0 | 147,382 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 76.96 per share. | 01 Sep 2022 | 1,750 | 92,875 (0%) | 0% | 77.0 | 134,677 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.93 per share. | 01 Sep 2022 | 1,200 | 94,625 (0%) | 0% | 75.9 | 91,114 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.68 per share. | 01 Sep 2022 | 1,088 | 89,067 (0%) | 0% | 78.7 | 85,602 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.94 per share. | 01 Sep 2022 | 1,047 | 101,146 (0%) | 0% | 75.9 | 79,504 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 79.04 per share. | 01 Sep 2022 | 584 | 87,397 (0%) | 0% | 79.0 | 46,158 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.66 per share. | 01 Sep 2022 | 452 | 95,825 (0%) | 0% | 78.7 | 35,556 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.14 per share. | 01 Sep 2022 | 438 | 88,029 (0%) | 0% | 78.1 | 34,225 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 77.06 per share. | 01 Sep 2022 | 360 | 88,467 (0%) | 0% | 77.1 | 27,742 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.88 per share. | 01 Sep 2022 | 240 | 88,827 (0%) | 0% | 75.9 | 18,210 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 78.96 per share. | 01 Sep 2022 | 48 | 87,981 (0%) | 0% | 79.0 | 3,790 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 69.66 per share. | 02 Aug 2022 | 414 | 102,193 (0%) | 0% | 69.7 | 28,839 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 59.07 per share. | 05 Jul 2022 | 312 | 102,607 (0%) | 0% | 59.1 | 18,431 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 70.10 per share. | 08 Mar 2022 | 744 | 102,295 (0%) | 0% | 70.1 | 52,154 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 30,422 | 30,422 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 17,371 | 104,524 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 4,933 | 4,933 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 03 Mar 2022 | 930 | 103,594 (0%) | 0% | 74.5 | 69,283 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 70.41 per share. | 03 Mar 2022 | 555 | 103,039 (0%) | 0% | 70.4 | 39,076 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 138.23 per share. | 02 Sep 2021 | 540 | 87,153 (0%) | 0% | 138.2 | 74,645 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 149.38 per share. | 02 Aug 2021 | 713 | 89,486 (0%) | 0% | 149.4 | 106,507 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 149.43 per share. | 02 Aug 2021 | 328 | 89,158 (0%) | 0% | 149.4 | 49,013 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 137.12 per share. | 06 Jul 2021 | 154 | 90,199 (0%) | 0% | 137.1 | 21,117 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 130.81 per share. | 08 Mar 2021 | 765 | 90,045 | - | 130.8 | 100,067 | Restricted Share Units |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 137.55 per share. | 04 Mar 2021 | 567 | 90,810 | - | 137.6 | 77,993 | Restricted Share Units |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 16,003 | 16,003 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 8,709 | 91,377 | - | 0 | Restricted Share Units | |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 152.05 per share. | 02 Mar 2021 | 430 | 82,668 | - | 152.1 | 65,383 | Restricted Share Units |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.10 per share. | 27 Feb 2021 | 1,465 | 83,098 (0%) | 0% | 149.1 | 218,432 | Ordinary Shares |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 1,465 | 0 | - | - | Restricted Stock Units | |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 11,336 | 11,336 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Frank Leonard | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 5,904 | 81,633 | - | 0 | Restricted Share Units |